Skip to content
myglp1coverage.com

Kaiser Permanente Southern California · Weight Loss

Kaiser Permanente Southern California coverage for Zepbound (Weight Loss)

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, dyslipidemia, CVD, CAD, OSA, osteoarthritis of the knee, polycystic ovarian syndrome, NASH/NAFLD, asthma, and COPD)
  • BMI of 27.5 or higher for patients of Asian descent
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Initial approval — BMI >= 30 kg/m2 (non-Asian)

All of:

  • Age 18 or older
  • BMI >= 30 kg/m2
  • Actively enrolled in exercise and caloric reduction program
  • Not using Zepbound concurrently with a GLP-1 receptor agonist

Initial approval — Asian patient BMI >= 27.5 kg/m2

All of:

  • Age 18 or older
  • Asian patient with BMI >= 27.5 kg/m2
  • Actively enrolled in exercise and caloric reduction program
  • Not using Zepbound concurrently with a GLP-1 receptor agonist

Initial approval — BMI >= 27 kg/m2 with comorbidity (non-Asian)

All of:

  • Age 18 or older
  • BMI >= 27 kg/m2
  • At least one weight-related comorbidity (hypertension, T2DM, dyslipidemia, cardiovascular disease, CAD, sleep apnea, osteoarthritis of the knee, polycystic ovarian syndrome, NASH/NAFLD, asthma, COPD)
  • Actively enrolled in exercise and caloric reduction program
  • Not using Zepbound concurrently with a GLP-1 receptor agonist

Initial approval — Asian patient BMI >= 25 kg/m2 with comorbidity

All of:

  • Age 18 or older
  • Asian patient with BMI >= 25 kg/m2
  • At least one weight-related comorbidity (hypertension, T2DM, dyslipidemia, cardiovascular disease, CAD, sleep apnea, osteoarthritis of the knee, polycystic ovarian syndrome, NASH/NAFLD, asthma, COPD)
  • Actively enrolled in exercise and caloric reduction program
  • Not using Zepbound concurrently with a GLP-1 receptor agonist

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2, or >= 27.5 kg/m2 for Asian patients, or >= 27 kg/m2 with comorbidity, or >= 25 kg/m2 for Asian patients with comorbidity)
  • Documentation of at least one weight-related comorbidity if using lower BMI threshold pathway
  • Documentation of active enrollment in exercise and caloric reduction program
  • Confirmation that Zepbound will not be used concurrently with a GLP-1 receptor agonist
  • At renewal: documentation of at least 5% weight loss from baseline body weight

Approval and renewal

  • To renew, the plan looks for at least 5% weight loss from the starting weight and Patient must have achieved or maintained at least 5% weight loss from baseline (pre-treatment) body weight. BMI eligibility thresholds are re-verified at renewal (same thresholds as initial). Age and lifestyle program enrollment requirements from initial criteria are not explicitly re-verified at renewal. Concurrent GLP-1 use remains prohibited. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Concurrent use of a GLP-1 receptor agonist (liraglutide, semaglutide, exenatide, exenatide extended-release)

Policy note: For Asian patients, the BMI threshold without comorbidity is 27.5 kg/m2 and with comorbidity is 25 kg/m2. For non-Asian patients, BMI threshold without comorbidity is 30 kg/m2 and with comorbidity is 27 kg/m2. At renewal, the BMI eligibility thresholds are re-verified using the same criteria as initial approval, plus the 5% weight loss requirement. The lifestyle program enrollment and age requirement are present in initial criteria but not explicitly listed in renewal criteria.

Policy effective June 1, 2026 · verified June 5, 2026 · source: Standard-Commercial-Guidelines-6-1-26-EXCERPTED.pdf

All Zepbound policies under Kaiser Permanente Southern California · Check your card